CN105727081A - Healthcare product composition for treating gout - Google Patents
Healthcare product composition for treating gout Download PDFInfo
- Publication number
- CN105727081A CN105727081A CN201610270299.1A CN201610270299A CN105727081A CN 105727081 A CN105727081 A CN 105727081A CN 201610270299 A CN201610270299 A CN 201610270299A CN 105727081 A CN105727081 A CN 105727081A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- halth
- care composition
- treating gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 23
- 241000962514 Alosa chrysochloris Species 0.000 claims abstract description 15
- 240000003394 Malpighia glabra Species 0.000 claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 13
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 13
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 12
- 240000008042 Zea mays Species 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 12
- 229940029339 inulin Drugs 0.000 claims abstract description 12
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 10
- 235000005822 corn Nutrition 0.000 claims abstract description 10
- 229940094952 green tea extract Drugs 0.000 claims abstract description 10
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 10
- -1 using is convenient Substances 0.000 claims abstract description 4
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 3
- 210000000582 semen Anatomy 0.000 claims description 21
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 11
- 235000009392 Vitis Nutrition 0.000 claims description 11
- 241000219095 Vitis Species 0.000 claims description 11
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 239000008347 soybean phospholipid Substances 0.000 claims description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 2
- 108010028690 Fish Proteins Proteins 0.000 claims description 2
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 claims description 2
- 229930182486 flavonoid glycoside Natural products 0.000 claims description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 235000009569 green tea Nutrition 0.000 claims description 2
- 229930182489 iridoid glycoside Natural products 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical group O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 claims description 2
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 abstract 1
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 241000167854 Bourreria succulenta Species 0.000 abstract 1
- 240000000560 Citrus x paradisi Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000014837 Malpighia glabra Nutrition 0.000 abstract 1
- 244000090599 Plantago psyllium Species 0.000 abstract 1
- 235000010451 Plantago psyllium Nutrition 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 235000019693 cherries Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000010903 husk Substances 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 24
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 22
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 20
- 229940116269 uric acid Drugs 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 241000234295 Musa Species 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000020805 dietary restrictions Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241001063885 Smilax pseudochina Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000026234 goat disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a healthcare product composition for treating gout and relates to the field of food therapy and healthcare product and traditional Chinese medicine preparation.The healthcare product composition is prepared from, by weight, 20-40 parts of inulin, 20-40 parts of corn oligopeptides, 2-5 parts of green banana meal, 8-20 parts of psyllium seed husk, 2-3 parts of hawthorn fruit powder, 3-10 parts of acerola cherry, 4-10 parts of grape fruit powder, 2-5 parts of granulesten, 2-5 parts of green tea extract and 10-20 parts of skipjack extract.The healthcare product composition can treat hyperuricemia (gout).Usually, gout is treated with drugs, however, the formula adopted for the healthcare product composition is based on food materials, using is convenient, material safety is high, and no obvious adverse reaction or toxic and side effect is generated.
Description
Technical field
The present invention relates to dietetic therapy and health product and Chinese medicine preparation field, relate more specifically to a kind of guarantor for treating gout
Strong product compositions.
Background technology
Gout is a kind of due to biosynthesis of purine metabolism increase, and uric acid produces too much or the hyperamization because urate excretion is bad
Middle uric acid raises, and urate crystal is deposited in synovium of joint, synovial bursa, cartilage and hetero-organization thereof the repeated relapsing inflammatory caused
Disease.Gout is caused by purine metabolic disturbance and underexcretion, and its sickness rate increases year by year.The sickness rate of various countries is different,
Nearly 10 annual morbidities in Asia are gradually increasing.Foreign data shows, the sickness rate of adult's hyperuricemia is up to 5%, the trouble of gout
Sick rate reaches 0.13% 0.37%.Along with improving constantly of our people's people life level, the dietary structure of people has the biggest
Change, high purine, high protein, higher fatty acid.Entering 21 century, goat has become the second largest metabolism of the mankind after diabetes
Disease.The inducement of gout outbreak, mainly due to taking in too much purine, makes serum uric acid level raise.
Current gouty arthritis Therapeutic Method includes taking good care of auxiliary treatment, acupuncture and moxibustion therapy and Drug therapy etc., but deposits
At western medicine DeGrain, side effect is big, take effect the problem such as slow.Therefore people are to rapid, effective treatment gouty joint
There is great demand in scorching Chinese medicine.
Summary of the invention
In order to solve the problems referred to above, it is an object of the invention to: provide one to provide a kind of determined curative effect, toxic and side effects
Little, safety high, metabolic arthritis can be reduced, have treatment gout function Halth-care composition.
In order to achieve the above object, the technical scheme is that a kind of Halth-care composition for treating gout, its
It is mixed to prepare by following percentage by weight by each component:
Inulin 20-40: be slightly cold;Pungent, bitter;Return lung, Liver Channel.Function cures mainly: heat-clearing and toxic substances removing;Dispelling wind suppressing the hyperactive liver.Cure mainly: furuncle;
Carbuncle;Erysipelas;Eczema;Dermatitis;Anemopyretic cold;Laryngopharynx swelling and pain;Hypertension;
Maize oligopeptide 20-40: sweet in the mouth, light, property is put down.Return bladder, liver, gallbladder meridian.Function cures mainly inducing diuresis to remove edema, suppressing the hyperactive liver profit
Gallbladder.For acute and chronic nephritis, edema, acute hepatitis, chronic hepatitis, hypertension, diabetes, chronic sinusitis, lithangiuria, biliary tract is tied
Stone, the disease such as dysuria, damp and hot jaundice;
Green banana powder 2-5: Fructus Musae, rich in potassium, contributes to reducing uric acid crystal and is deposited in joint, help body discharges urine
Acid;
Circle bud Semen Plantaginis shell 8-20: feeble QI, lightly seasoned.Sweet, cold.Return liver, kidney, lung, small intestine meridian.Clearing away heat and promoting diuresis is treating stranguria, eliminating dampness by diuresis
Antidiarrheal, improving eyesight, eliminate the phlegm.For the puckery pain of pyretic stranguria, edema distension, diarrhea due to summer heat and dampness, conjunctival congestion and swelling pain, phlegm-heat cough;
Fructus Crataegi powder 2-3: acid is sweet, tepor.Enter spleen, stomach, Liver Channel.Help digestion long-pending, dissipating blood stasis blood, expelling tenia.Control meat to amass, lump in the abdomen, expectorant
Drink, feeling of fullness, acid regurgitation, dysentery, hemorrhoidal hamorrhage, lumbago, hernia after-pains in puerperal, lochiorrhea, children's's breast food is stagnated.Promoting digestion and invigorating the stomach, OK
Gas dissipating blood stasis.For meat stagnation, stomach alkane distension, dysentery stomachache, blood stasis amenorrhea, postpartum stagnation, trusted subordinate's twinge, hernia pain, height
Blood fat disease;
Malpighia glabra L. 3-10: the Malpighia glabra L. vitamin C containing superelevation amount, simultaneously possibly together with dimension A, dimension B1, dimension B2, ferrum, calcium
Deng element, vitamin C is the important composition maintaining human life integral, and vitamin C can not only promote that glomerulonephritis is little
The permeability of pipe blood capillary, beneficially urate excretion, and participate in the biochemical reaction of internal many enzymes, promote internal metabolism, divide
Solve more purine.Generation from Sources controlling blood uric acid;It can anti-be caught a cold, anti-vitamin C deficiency, improves human body resistivity, right
Beauty treatment and cancer have certain effect, primary efficacy: nutritional labeling contained by Malpighia glabra L. is comprehensive, content is high;As nutrient substance,
It can with diuresis, alleviate cardiac function, it can also assist treatment gout, anemia, diabetes, hypercholesterolemia, liver, rheumatism,
Pulmonary tuberculosis etc.;
Full Fructus Vitis viniferae fruit powder 4-10: full Fructus Vitis viniferae fruit powder is one layer of powdery waxy substance, is a kind of triterpene (triterpene), tool
There are the functions such as suppression oral cavity Streptococcus mutans (Streptococcus mutans), aging resistance by lipid material synthesis in fruit
Come, have disease-resistant, prevent the effects such as moisture evaporation;
Soybean phospholipid 2-5: soybean phospholipid not only has stronger emulsifying, moistening, peptizaiton, is also promoting body fat
The aspects such as metabolism, muscle growth, nervous system development and internal anti-oxidative damage play critically important effect, can suppress enteral
The absorption of cholesterol, therefore blood cholesterol levels and lipotropic effect can be reduced;The present invention is made to expand applicable crowd;
Green tea extract 2-5: tea polyphenols has stronger antioxidation, especially ester catechin EGCG, its reproducibility
Even up to 100 times of the different bad hematic acid of L-, also have formation and the summation of suppression nitrite, effectively alleviate goat
Disease;
Skipjack extract 10-20: it is demonstrated experimentally that Skipjack extract through ferment decompose the oligopeptide of gained, free amino acid with
And glucosan, can help to have the formation of the gout sufferer suppression uric acid of a large amount uric acid, by unnecessary uric acid from internal removing, acting on
In kidney to help health to reduce uric acid, suppress to be converted into xanthine xanthine element oxidasic activity, the Yi Jijia of uric acid
Furosemide acid is gone out from internal secretion.
The beneficial effects of the present invention is: the present invention mainly improves uric acid by diatery supplement, purine in dietary restriction
Supply, safety is high and convenient.This formula can reduce the absorption of exogenous purine, promotes the excretion of uric acid, reduces purine generation
The burden thanked.
As a further improvement on the present invention, it is mixed to prepare by following percentage by weight by each component:
Inulin 25-35
Corn oligopeptide powder 25-36
Green banana powder 2-3.5
Circle bud Semen Plantaginis shell 10-18
Fructus Crataegi powder 2.5
Malpighia glabra L. 5-8
Full Fructus Vitis viniferae fruit powder 5-8
Soybean phospholipid 4
Green tea extract 3-5
Skipjack extract 12-17.
As a further improvement on the present invention, also including resistant dextrin, the percentage by weight of described resistant dextrin is 4-
10, the percentage by weight of the most described resistant dextrin is 5-8.From the point of view of the anti-digestive enzyme action characteristic that resistant dextrin is had,
It is a kind of food material with lower caloric, and owing to will not digested absorb in digestive tract, can be directly entered large intestine, therefore,
Various physiological actions can be played as dietary fiber.The hypoglycemic function of fall that resistant dextrin has, research shows, every day takes the photograph people
A certain amount of resistant dextrin can effectively prevent the various symptoms of diabetes patient, makes to present invention can be suitably applied to diabetes patient and uses.
As a further improvement on the present invention, also include that Semen Coicis or Poria extract, described Semen Coicis or Poria carry
Taking thing percentage by weight is 3-10.Preferably, described Semen Coicis or Poria extract percentage by weight are 5-7.Semen Coicis has
Spleen invigorating, tonifying the lung, heat clearing away, dampness removing, control and have loose bowels, arthralgia chiefly caused by damp pathogen, muscle arteries and veins contracture, joint stuffiness, edema, tinea pedis, consumptive lung disease, lung abscess, acute appendicitis, drenches
Turbid, leucorrhea.Poria is that Liliaceae perennial evergreen climbs shape shrub, and part of being used as medicine only selects its dried rhizome." book on Chinese herbal medicine guiding principle
Mesh " to record: strengthening the spleen and stomach, bone and muscle strengthening, curing rheumatism, profit joint, stopping leak rushes down.Control contracture osteodynia;Malignant boil carbuncle.Solve hydrargyrum powder, Vermilion poison.
Rhizome contains Saponin, tannin, resin etc..The root of congener Smilax pseudo-china contains alkaloid, volatile oil, hexose, tan
Matter, plant sterol and linoleic acid, oleic acid etc..
As a further improvement on the present invention, described green tea extract effective ingredient is tea polyphenols.
As a further improvement on the present invention, described Skipjack extract effective ingredient is double peptide fish protein.
As a further improvement on the present invention, described circle bud Semen Plantaginis shell effective ingredient be verbascoside, phenethyl alcohol glycoside,
Flavonoid glycoside and iridoid glycoside.Semen Plantaginis has clearing away heat and promoting diuresis, and eliminating dampness by diuresis is treating stranguria, improving eyesight, the effect eliminated the phlegm.Semen Plantaginis extract exists
External can preferably suppress XOD activity.There is significantly fall blood uric acid effect in vivo, its inhibitory action mechanism and suppression XOD
Activity is closely related, and also has and can reduce cytotoxicity, improves renal function and promotes urate excretion effect.Gout be due to
Purine substance metabolism disorder, produces uric acid too much and (or) underexcretion, and serum Uric Acid Concentration persistently increases and causes uric acid
The salt-pepper noise deposition one group of metabolic disease caused by soft tissue, and the hyperuricemia most important biochemical basis that is gout.Pass through
Suppress internal xanthine oxidase compound enzyme (XOD) activity or promote that the excretion of uric acid can effectively prevent and treat gout.Suppression XOD activity at present
Show that Semen Plantaginis has important antigout drug Development volue.
As a further improvement on the present invention, described compositions makes tablet, capsule, pill, granule or powder.
Detailed description of the invention
In order to make the purpose of the present invention, technical scheme and advantage become apparent from understanding, further describe it.
Embodiment 1
By weight percentage by the inulin of 25 parts, the corn oligopeptide powder of 28 parts, the green banana powder of 2 parts, the circle of 13.5 parts
Bud Semen Plantaginis shell, the Fructus Crataegi powder of 2.5 parts, the Malpighia glabra L. of 5 parts, the full Fructus Vitis viniferae fruit powder of 5 parts, the soybean phospholipid of 4 parts, 3 parts green
Tea extract and the Skipjack extract mixing of 12 parts, and make tablet, capsule, pill, granule or powder.
Embodiment 2
By weight percentage by the inulin of 26 parts, the corn oligopeptide powder of 27 parts, the green banana powder of 2 parts, the circle bud of 10 parts
Semen Plantaginis shell, the Fructus Crataegi powder of 2.5 parts, the Malpighia glabra L. of 5 parts, the full Fructus Vitis viniferae fruit powder of 5 parts, the soybean phospholipid of 4 parts, the green tea of 3 parts
Extract and the Skipjack extract mixing of 15.5 parts, and make tablet, capsule, pill, granule or powder.
Embodiment 3
By weight percentage by the inulin of 25 parts, the corn oligopeptide powder of 26 parts, the green banana powder of 2 parts, the circle bud of 10 parts
Semen Plantaginis shell, the Fructus Crataegi powder of 2.5 parts, the Malpighia glabra L. of 5 parts, the full Fructus Vitis viniferae fruit powder of 5 parts, the soybean phospholipid of 4 parts, 3.5 parts green
Tea extract, the Skipjack extract of 12 parts and 5 parts of Semen Coiciss or Poria extract mixing, and make tablet, capsule, pill,
Granule or powder.
Embodiment 4
By weight percentage by the inulin of 25 parts, the corn oligopeptide powder of 26 parts, the green banana powder of 2 parts, the circle of 10.5 parts
Bud Semen Plantaginis shell, the Fructus Crataegi powder of 2.5 parts, the Malpighia glabra L. of 5 parts, the full Fructus Vitis viniferae fruit powder of 5 parts, the soybean phospholipid of 4 parts, 3 parts green
Tea extract, the Skipjack extract of 12 parts and 5 parts of resistant dextrin mixing, and make tablet, capsule, pill, granule or powder
Agent.
Embodiment 5
By weight percentage by the inulin of 25 parts, the corn oligopeptide powder of 25 parts, the green banana powder of 2 parts, the circle bud of 10 parts
Semen Plantaginis shell, the Fructus Crataegi powder of 2.5 parts, the Malpighia glabra L. of 5 parts, the full Fructus Vitis viniferae fruit powder of 5 parts, the soybean phospholipid of 4 parts, 3.5 parts green
Tea extract, the Skipjack extract of 12 parts and the mixing of 6 parts of Poria extracts, and make tablet, capsule, pill, granule or
Powder.
The present invention mainly improves uric acid by diatery supplement, the supply of purine in dietary restriction, and safety is high and convenient.This
Formula can reduce the absorption of exogenous purine, promotes the excretion of uric acid, reduces the burden of purine metabolism.Its recipe ingredient includes
Corn oligopeptide powder, inulin, circle bud Semen Plantaginis shell, Malpighia glabra L. powder, full Fructus Vitis viniferae fruit powder, soybean lecithin, Skipjack extract etc..
Wherein maize oligopeptide is low purine albumen, as the albumen supplementary source of high-quality, can alleviate the complication of the patient of gout, promote
The excretion of uric acid.It addition, inulin is for preventing and treat the safety height of gout.Circle bud Semen Plantaginis shell, Malpighia glabra L. powder, Skipjack
The components such as extract have the effect reducing metabolic arthritis.Formula is based on raw-food material, easy to use, raw material in formula
Safety is high, has no obvious untoward reaction and toxicity.
The announcement of book and teaching according to the above description, those skilled in the art in the invention can also be to above-mentioned embodiment party
Formula carries out suitable change and amendment.Therefore, the invention is not limited in detailed description of the invention disclosed and described above, to this
Some modifications and changes of invention should also be as falling in the scope of the claims of the present invention.Although additionally, this specification
In employ some specific terms, but these terms are merely for convenience of description, and the present invention does not constitute any restriction.
Claims (10)
1. the Halth-care composition being used for treating gout, it is characterised in that: it is mixed by following percentage by weight by each component
Close and prepare:
Inulin 20-40
Corn oligopeptide powder 20-40
Green banana powder 2-5
Circle bud Semen Plantaginis shell 8-20
Fructus Crataegi powder 2-3
Malpighia glabra L. 3-10
Full Fructus Vitis viniferae fruit powder 4-10
Soybean phospholipid 2-5
Green tea extract 2-5
Skipjack extract 10-20.
Halth-care composition for treating gout the most according to claim 1, it is characterised in that: its by each component by with
Lower percentage by weight is mixed to prepare:
Inulin 25-35
Corn oligopeptide powder 25-36
Green banana powder 2-3.5
Circle bud Semen Plantaginis shell 10-18
Fructus Crataegi powder 2.5
Malpighia glabra L. 5-8
Full Fructus Vitis viniferae fruit powder 5-8
Soybean phospholipid 4
Green tea extract 3-5
Skipjack extract 12-17.
Halth-care composition for treating gout the most according to claim 1 and 2, it is characterised in that: also include anti-
Property dextrin, the percentage by weight of described resistant dextrin is 4-10.
Halth-care composition for treating gout the most according to claim 3, it is characterised in that described resistant dextrin
Percentage by weight is 5-8.
Halth-care composition for treating gout the most according to claim 1 and 2, it is characterised in that also include Semen Coicis
Core or Poria extract, described Semen Coicis or Poria extract percentage by weight are 3-10.
Halth-care composition for treating gout the most according to claim 5, it is characterised in that described Semen Coicis or
Poria extract percentage by weight is 5-7.
Halth-care composition for treating gout the most according to claim 1 and 2, it is characterised in that described green tea carries
Taking thing effective ingredient is tea polyphenols.
Halth-care composition for treating gout the most according to claim 1 and 2, it is characterised in that described Skipjack carries
Take thing effective ingredient for double peptide fish protein.
Halth-care composition for treating gout the most according to claim 1 and 2, it is characterised in that described circle bud car
Front sub-shell effective ingredient is verbascoside, phenethyl alcohol glycoside, flavonoid glycoside and iridoid glycoside.
10. according to the Halth-care composition for treating gout described in claim 1 to 5 any one, it is characterised in that institute
State compositions and make tablet, capsule, pill, granule or powder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610270299.1A CN105727081A (en) | 2016-04-26 | 2016-04-26 | Healthcare product composition for treating gout |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610270299.1A CN105727081A (en) | 2016-04-26 | 2016-04-26 | Healthcare product composition for treating gout |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105727081A true CN105727081A (en) | 2016-07-06 |
Family
ID=56287505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610270299.1A Pending CN105727081A (en) | 2016-04-26 | 2016-04-26 | Healthcare product composition for treating gout |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105727081A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722990A (en) * | 2016-12-19 | 2017-05-31 | 叶子豪 | A kind of food with reducing blood pressure and blood fat anti-trioxypurine |
CN106901382A (en) * | 2017-02-27 | 2017-06-30 | 济南蜃骊医药科技有限公司 | A kind of health care preparation for treating pregnant woman's flu |
CN109122859A (en) * | 2018-11-01 | 2019-01-04 | 威海健康生生物科技有限公司 | Anti-trioxypurine composition and the preparation method and application thereof |
CN109430667A (en) * | 2018-10-19 | 2019-03-08 | 张东祥 | A kind of composition and solid beverage with anti-trioxypurine effect |
CN110150662A (en) * | 2019-05-29 | 2019-08-23 | 山东腾贵医药有限公司 | The comprehensive generation meal and preparation method thereof that a kind of couple of gout crowd maintains for a long time |
CN111134329A (en) * | 2018-11-06 | 2020-05-12 | 深圳华大生命科学研究院 | Application of plant polysaccharide in preparation of intestinal type-related hyperuricemia drug |
CN111617231A (en) * | 2019-11-01 | 2020-09-04 | 北京同仁堂健康药业股份有限公司 | Uric acid-reducing and anti-gout composition as well as preparation method and application thereof |
WO2021007067A1 (en) * | 2019-07-09 | 2021-01-14 | Brauus Llc | Food composition comprising green banana and inulin |
CN112914100A (en) * | 2021-03-03 | 2021-06-08 | 广西香蕉谷科技有限公司 | Production equipment and process method of uric acid-reducing food for promoting absorption and metabolism of human body |
CN113456741A (en) * | 2021-07-21 | 2021-10-01 | 武汉英纽林生物科技有限公司 | Composition for preventing hyperuricemia and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104855985A (en) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | Non-complete-nutrition formula food for high uric acid |
-
2016
- 2016-04-26 CN CN201610270299.1A patent/CN105727081A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104855985A (en) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | Non-complete-nutrition formula food for high uric acid |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722990A (en) * | 2016-12-19 | 2017-05-31 | 叶子豪 | A kind of food with reducing blood pressure and blood fat anti-trioxypurine |
CN106901382A (en) * | 2017-02-27 | 2017-06-30 | 济南蜃骊医药科技有限公司 | A kind of health care preparation for treating pregnant woman's flu |
CN109430667A (en) * | 2018-10-19 | 2019-03-08 | 张东祥 | A kind of composition and solid beverage with anti-trioxypurine effect |
CN109122859A (en) * | 2018-11-01 | 2019-01-04 | 威海健康生生物科技有限公司 | Anti-trioxypurine composition and the preparation method and application thereof |
CN111134329A (en) * | 2018-11-06 | 2020-05-12 | 深圳华大生命科学研究院 | Application of plant polysaccharide in preparation of intestinal type-related hyperuricemia drug |
CN110150662A (en) * | 2019-05-29 | 2019-08-23 | 山东腾贵医药有限公司 | The comprehensive generation meal and preparation method thereof that a kind of couple of gout crowd maintains for a long time |
WO2021007067A1 (en) * | 2019-07-09 | 2021-01-14 | Brauus Llc | Food composition comprising green banana and inulin |
CN111617231A (en) * | 2019-11-01 | 2020-09-04 | 北京同仁堂健康药业股份有限公司 | Uric acid-reducing and anti-gout composition as well as preparation method and application thereof |
CN112914100A (en) * | 2021-03-03 | 2021-06-08 | 广西香蕉谷科技有限公司 | Production equipment and process method of uric acid-reducing food for promoting absorption and metabolism of human body |
CN113456741A (en) * | 2021-07-21 | 2021-10-01 | 武汉英纽林生物科技有限公司 | Composition for preventing hyperuricemia and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105727081A (en) | Healthcare product composition for treating gout | |
CN101695376A (en) | Health-care food for preventing diabetes | |
KR20140126087A (en) | Beverages that always immune function and antioxidant substances | |
CN105942498A (en) | Functional nutritional food compounds with diabetes-treating effects and preparation methods thereof | |
CN105412623A (en) | Medicament for treating fatty liver, prostatitis, nephralgia, nephritis, hypertension and diabetes | |
CN105079465A (en) | Composition capable of lowering blood glucose | |
CN111109602A (en) | Medicated functional food suitable for people with diabetes and hyperlipidemia obesity | |
CN106937741A (en) | A kind of degreasing linseed meal cancer-resisting health slimming method and preparation method thereof | |
CN103749824B (en) | A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof | |
CN101862411B (en) | Chinese medicinal composition for treating acne | |
CN113855766A (en) | Gingko and cordyceps militaris granules capable of regulating blood pressure | |
CN105249440A (en) | Donkey-hide gelatin cake | |
CN117599140A (en) | Traditional Chinese medicine composition for reducing blood sugar, blood pressure and blood fat and preparation and application thereof | |
CN104873826A (en) | Tea drink capable of clearing away lung heat and dispelling damp and preparation method thereof | |
CN105685994A (en) | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction | |
CN105311375A (en) | Composition for reducing blood lipid | |
CN106307506A (en) | Chinese traditional therapeutic method for diabetes | |
CN106578199A (en) | Oral solution for preventing malignant tumors | |
CN103340991B (en) | Oral liquid for nursing diabetics and preparation method thereof | |
CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
CN105410926A (en) | Long-stem grape caulerpa capsule capable of reducing weight and preparation method of long-stem grape caulerpa capsule | |
CN105250747A (en) | Health maintenance paste | |
CN105105127A (en) | Multifunctional health food of haw heart easing powder | |
CN104305179B (en) | Broad-spectrum high efficacy mind calming active blood pressure lowering fat reducing functional food and preparation method thereof | |
CN106177514A (en) | A kind of medicine treating fatty liver, prostatitis, diabetes, hypertension, pneumonia, gastroenteritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |